SCLXW:NSD- (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.389

Change

+0.03 (+8.06)%

Market Cap

N/A

Volume

0.02M
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-26 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-0.19 (-0.24%)

USD 245.19B
AMGN Amgen Inc

-1.24 (-0.40%)

USD 170.67B
SNY Sanofi ADR

+0.44 (+0.92%)

USD 122.04B
GILD Gilead Sciences Inc

-0.22 (-0.32%)

USD 80.07B
BIIB Biogen Inc

+3.10 (+1.36%)

USD 32.56B
GRFS Grifols SA ADR

+0.01 (+0.08%)

USD 5.90B
AMRN Amarin Corporation PLC

-0.01 (-1.84%)

USD 0.29B
SCLX Scilex Holding Company

+0.14 (+7.82%)

USD 0.18B
MIRA MIRA Pharmaceuticals Inc. Comm..

-0.01 (-2.00%)

USD 0.01B

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.06% 80% B- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.06% 80% B- 72% C
Trailing 12 Months  
Capital Gain -74.07% 22% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.07% 22% F 11% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -14.97% 44% F 22% F
Dividend Return -14.97% 44% F 22% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.34% 11% F 36% F
Risk Adjusted Return -31.63% 44% F 26% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector